Introduction {#Sec1}
============

*Propionibacterium acnes* contributes to inflammatory acne by stimulating keratinocytes, sebocytes, and immune cells to produce multiple proinflammatory cytokines such as interleukin (IL)-1α, tumor necrosis factor (TNF)-α, and chemokines (e.g., IL-8), which, in turn, attract neutrophils and mononuclear cells to the pilosebaceous unit \[[@CR1]--[@CR8]\]. *P. acnes* can also directly cause tissue injury \[[@CR9]--[@CR13]\]. In addition, *P. acnes* can activate inflammasomes and induce IL-1β secretion from monocytes \[[@CR14], [@CR15]\]. Toll-like receptors (TLRs) and nuclear factor kappa B (NF-κB) are involved in *P. acnes*-induced inflammation \[[@CR4], [@CR16]--[@CR19]\]. Microbial products and cytokines act through the Toll-like, IL-1, and TNF receptor families to activate mitogen-activated protein kinases (MAPKs), leading to the activation of NF-κB \[[@CR20]--[@CR25]\]. Very few studies have investigated which MAPK may mediate the proinflammatory response \[[@CR26], [@CR27]\].

There are three major groups of MAPKs: the extracellular signal-related kinases (ERK1/2), the c-Jun N-terminal kinases (JNK1/2), and the p38 MAPKs (α, β, γ, and $\documentclass[12pt]{minimal}
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                \begin{document}$$ \delta $$\end{document}$) \[[@CR20], [@CR28]--[@CR36]\]. ERKs are predominantly activated by mitogenic factors, while JNK and p38 are preferentially activated by proinflammatory cytokines and stress-inducing stimuli \[[@CR33]\]. For p38 MAPKs, α and β are ubiquitously expressed, whereas γ and $\documentclass[12pt]{minimal}
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                \begin{document}$$ \delta $$\end{document}$ are expressed in more restricted patterns \[[@CR37]\]. In human keratinocytes, p38α and β are involved in responses to stress and proinflammatory cytokines, while p38$\documentclass[12pt]{minimal}
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                \begin{document}$$ \delta $$\end{document}$ has been implicated in keratinocyte differentiation \[[@CR38]\]. p38 MAPKs have been implicated in inflammatory disease pathways such as psoriasis, asthma, and Crohn's disease and the p38α kinase might play a central role in inflammation \[[@CR35], [@CR39]\].

Inhibitors of p38 serve as valuable tools for elucidating the role of that enzyme in inflammatory responses. SB203580 is an inflammatory cytokine inhibitor that blocks both p38α and p38β kinase activities \[[@CR37]\]. SCIO-469 is a relatively selective inhibitor of the α isoform of p38 \[[@CR40]\]. Topical administration of SCIO-469 reduced acute skin inflammation in guinea pigs \[[@CR41]\].

p38 regulates the production of inflammatory mediators that stimulate leukocyte recruitment and activation \[[@CR42]\]. Many of these mediators (e.g., IL-1, TNF-α, and IL-8) are secreted by keratinocytes in response to *P. acnes* \[[@CR5]--[@CR7]\]. Thus, the purpose of this study was to evaluate whether the *P. acnes*-induced proinflammatory cytokine release is mediated by *P. acnes*-induced activation of p38 mitogen-activated protein kinase (p38 MAPK or p38) in human keratinocytes.

Methods {#Sec2}
=======

p38 Inhibitors {#Sec3}
--------------

SCIO-469 was provided by Scios Inc. (Fremont, CA, USA) \[[@CR40]\]. SB203580 was purchased from Sigma (St. Louis, MO, USA).

Cell Culture {#Sec4}
------------

Normal human neonatal epidermal keratinocytes were obtained from Cascade Biologics (Portland, OR, USA) and maintained in keratinocyte growth medium (KGM) (Cascade Biologics, Inc., Portland, OR, USA). All experiments were performed between passages 2--4 and at 70--80% cell confluence. KGM was used as antibiotic free in all the experiments described in this paper.

*Propionibacterium acnes* {#Sec5}
-------------------------

*Propionibacterium acnes* strain ATCC 11828 was obtained from American Type Culture Collection (Manassas, VA, USA). Bacteria were grown for 48--72 h to reach stationary phase. Live bacteria were then harvested and re-suspended in KGM to achieve 10^8^ CFU/mL for in vitro experiments.

Tissue Specimens {#Sec6}
----------------

Five human acne lesional biopsies (three papules, one pustule, and one cystic acne) and five healthy scalp/neck skin were kindly provided by Drs. Jack L. Arbiser (Department of Dermatology, Emory University, Atlanta, GA, USA) and James J. Leyden (Department of Dermatology, University of Pennsylvania, PA, Philadelphia, USA) with informed consent. Five-micrometer-thick sections of biopsies were processed for immunostaining with rabbit anti-human phospho-p38 MAPK (Thr180/Tyr182) antibody (Cell Signaling Technology Inc., Danvers, MA, USA) \[[@CR43]\].

The immunohistochemical assessment was done by visually assessing the intensity of the signal (brown color) in acne lesions vs healthy skin. A representative image of acne lesions was chosen with strong (dark brown color) nuclear staining of phospho-p38 and that of healthy skin was chosen with no/weak (no color/light brown color) nuclear staining of phospho-p38 in follicular and perifollicular epidermal keratinocytes.

Human Epidermal Equivalents {#Sec7}
---------------------------

Human epidermal equivalents were purchased from MatTek Company (Asland, MA, USA). Upon receipt, human epidermal equivalents were incubated in EPI-100-ASY antibiotic-free MatTek assay medium overnight and then changed to KGM for another overnight incubation before topical treatment.

Enzyme-Linked Immunosorbent Assay (ELISA) {#Sec8}
-----------------------------------------

The protocol was adapted from Graham et al. \[[@CR14]\] with modifications. In brief, human primary keratinocytes were pre-incubated for 1 h with either p38 inhibitors or with vehicle, and the treatments were stopped. The keratinocytes were then exposed to stationary-phase *P. acnes* (at a ratio of *P. acnes* to keratinocytes of 50:1) and were co-cultured for 16 h at 37 °C. As for human epidermal equivalents, they were topically treated with either vehicle or the p38 inhibitors for 2 h, followed by changing the medium to KGM in either absence or presence of live stationary-phase *P. acnes* at 10^8^ CFU/mL for 16 h. After incubation, the supernatants were analyzed using Beadlyte^®^ human multi-cytokine ELISA beadmaster™ Assays (Upstate Cell Signaling Solution, Lake Placid, NY, USA). Results are presented as the mean ± SD of eight replicate wells for keratinocytes or of two equivalents, in which triplicates were collected from each equivalent. Half-maximal inhibitory concentrations (IC~50~'s) were calculated using SigmaPlot Version 9.0 (Csystat Software Inc., San Jose, CA, USA).

Lactate dehydrogenase (LDH) assays (G-Biosciences, St. Louis, MO, USA) were performed in all the supernatants to ensure no cytotoxicity occurred in the cells under the experimental conditions.

Western Analysis {#Sec9}
----------------

Activation of p38, ERK1/2, and JNK in human primary keratinocytes or epidermal equivalents was evaluated by Western blot using phospho-specific antibodies, and was normalized to the total level of the relevant proteins using anti-p38, anti-ERK1/2, and anti-JNK1/2 antibodies. Antibodies for phospho-p38 (Thr180/Tyr182), p38, phospho-p44/42 or ERK1/2 (Thr202/Tyr204), p44/42, phospho-SAPK/JNK (Thr183/Tyr185), SAPK/JNK, as well as goat anti-rabbit IgG HRP (horseradish peroxidase) and horse anti-mouse IgG HRP secondary antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). All other reagents for Western blot were purchased from Sigma (St. Louis, MO, USA), and blotting equipment was purchased from Bio-Rad (Hercules, CA, USA). The separated proteins were visualized by an ECL kit according to the manufacturer's protocol (GE Healthcare Bio-Sciences Co., Piscataway, NJ, USA) and quantitated by densitometric analysis using a Kodak Gel Logic 100 Imaging System and Kodak 1D Imaging Software (Eastman Kodak Co., New Haven, CT, USA).

Statistics {#Sec10}
----------

Statistical analyses were performed using two-tailed Student's *t* tests with unequal variances (Microsoft Office Excel 2007; Microsoft, Redmond, WA, USA). Differences were considered statistically significant if *p* \< 0.05 (\*), and highly significant if *p* \< 0.01 (\*\*) or *p* \< 0.005 (\*\*\*).

Compliance with Ethics Guidelines {#Sec11}
---------------------------------

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study.

Results {#Sec12}
=======

Activation of p38 in Human Acne Lesions {#Sec13}
---------------------------------------

Phospho-p38 expression was detected in all five acne tissue samples with a nuclear localization. A representative image of healthy skin shows mainly diffuse cytoplasmic staining of phospho-p38 in both epidermal and dermal cells (Fig. [1](#Fig1){ref-type="fig"}a), and weak nuclear staining in some hair follicle cells (Fig. [1](#Fig1){ref-type="fig"}b). In contrast, markedly increased level of phospho-p38 was observed in the inflammatory acne lesion (Fig. [1](#Fig1){ref-type="fig"}c). The phospho-p38 was mostly confined to the nuclei of follicular and perifollicular epidermal keratinocytes (Fig. [1](#Fig1){ref-type="fig"}d).Fig. 1p38 is activated in human acne lesions. **a** Healthy human skin shows diffuse cytoplasmic staining in both epidermis and dermis. **b** High magnification insert of **a** illustrates weak nuclear staining in some hair follicle cells of a healthy skin. **c** Strong nuclear staining of phospho-p38 is found in follicular and perifollicular epidermis and dermis of a representative human inflammatory acne lesion. **d** High magnification insert of **c** demonstrates a *solid dot* pattern of nuclear staining phospho-p38. *Bar* 100 µm

*Propionibacterium acnes* Induces a Time-Dependent Activation of MAPKs in Keratinocytes {#Sec14}
---------------------------------------------------------------------------------------

Stationary-phase *P. acnes* stimulated rapid (within 5 min) phosphorylation of both p38 (phospho-p38) and ERK1/2 (phospho-ERK1/2), with peaks at 15 min (Fig. [2](#Fig2){ref-type="fig"}a). There was up to a sevenfold increase in phosphorylation of p38 and ERK1/2, compared to untreated (Fig. [2](#Fig2){ref-type="fig"}b, c). An additional activation peak of phospho-ERK1/2 occurred between 2 and 4 h (approximately sixfold increase; Fig. [2](#Fig2){ref-type="fig"}a, c). *P. acnes* also induced relatively slow but sustained phosphorylation of JNK1/2 (phospho-JNK1/2); the maximum increase was approximately fourfold between 2 and 8 h (Fig. [2](#Fig2){ref-type="fig"}a, d). These results show that viable *P. acnes* induced the activation of multiple MAPK pathways in cultured human keratinocytes.Fig. 2*Propionibacterium acnes* induces activation of multiple MAPK pathways in cultured human keratinocytes. **a** Western blots show time-dependent induction of phospho-p38 (p-p38), phospho-ERK1/2 (p-ERK1/2) and phospho-JNK1/2 (p-JNK1/2). **b--d** The density of each phosphorylated MAPK band was normalized to its loading control, and then compared to time 0. *MAPK* mitogen-activated protein kinase, *ERK* extracellular signal-related kinases, *JNK* c-Jun N-terminal kinases

*Propionibacterium acnes*-Induced Phospho-p38 and Secretion of Cytokines are Suppressed by SB203580 {#Sec15}
---------------------------------------------------------------------------------------------------

Pretreatment of the keratinocytes with SB203580 at 10 and 25 μM reduced *P. acnes*-induced phospho-p38 to basal levels (Fig. [3](#Fig3){ref-type="fig"}a). Stationary-phase *P. acnes* stimulated the production of TNF-α (Fig. [3](#Fig3){ref-type="fig"}b) and IL-8 (Fig. [3](#Fig3){ref-type="fig"}c). Pretreatment of keratinocytes with SB203580 significantly suppressed *P. acnes*-induced secretion of TNF-α and IL-8 (Fig. [3](#Fig3){ref-type="fig"}b, c, both *p* \< 0.005).Fig. 3*Propionibacterium acnes*-induced phospho-p38 and cytokine release in keratinocyte cultures was inhibited by a p38α/β inhibitor, SB203580. **a** Western blots show that SB203580 inhibits *P. acnes*-induced phospho-p38. **b**--**c** SB203580 inhibits the secretion of TNF-α (**b**) and IL-8 (**c**). Data are expressed as mean ± SD. *p* \< 0.05 (\*), *p* \< 0.01 (\*\*), *p* \< 0.005 (\*\*\*). *TNF* tumor necrosis factor, *PA Propionibacterium acnes*, *Veh* vehicle

*Propionibacterium acnes*-Induced Activation of p38, but not ERK1/2 and JNK1/2, and Inflammatory Cytokine/Chemokine Secretion in Keratinocytes is Dose-Dependently Inhibited by SCIO-469 {#Sec16}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pretreatment of the keratinocytes with SCIO-469 inhibited *P. acnes*-induced phospho-p38 in a dose-dependent fashion with a 50% inhibition at 16--80 nM, and complete inhibition was observed between 0.4 and 2 μM (Fig. [4](#Fig4){ref-type="fig"}a). There was no inhibition but upregulation of *P. acnes* induced either phospho-ERK1/2 or phospho-JNK1/2 (Fig. [4](#Fig4){ref-type="fig"}a). Stationary-phase *P. acnes* stimulated the production of TNF-α (Fig. [4](#Fig4){ref-type="fig"}b, *p* \< 0.005), IL-8 (Fig. [4](#Fig4){ref-type="fig"}c, *p* \< 0.005), and IL-1α (Fig. [4](#Fig4){ref-type="fig"}d, *p* \< 0.005). Pretreatment of keratinocytes with SCIO-469 dose-dependently inhibited *P. acnes*-induced TNF-α secretion with an IC~50~ of 79 nM (Fig. [4](#Fig4){ref-type="fig"}b). SCIO-469 also significantly suppressed IL-8 and IL-1α secretion (Fig. [4](#Fig4){ref-type="fig"}c, d), but the degree of suppression was less for IL-8 and IL-1α than that observed for TNF-α.Fig. 4*Propionibacterium acnes*-induced phosphorylation of p38, but not of ERK1/2 or JNK1/2, and the cytokine release was inhibited by a p38α inhibitor, SCIO-469, in human keratinocytes. **a** Western blots show that SCIO-469 inhibits *P. acnes*-induced phospho-p38 (p-p38) dose-dependently, but not of phospho-ERK1/2 (p-ERK1/2) or phospho-JNK1/2 (p-JNK1/2). **b**--**c** SCIO-469 inhibits the secretion of TNF-α (**b**), IL-8 (**c**), and IL-1α (**d**). Data are expressed as mean ± SD. *p* \< 0.05 (\*), *p* \< 0.01 (\*\*), *p* \< 0.005 (\*\*\*). *ERK* extracellular signal-related kinases, *JNK* c-Jun N-terminal kinases, *TNF* tumor necrosis factor, *IL* interleukin, *PA Propionibacterium acnes*

Topical SCIO-469 Inhibits *P. acnes*-Induced Phospho-p38 and Secretion of Cytokines in Human Epidermal Equivalents {#Sec17}
------------------------------------------------------------------------------------------------------------------

Viable *P. acnes* induced both phospho-p38, and secretion of TNF-α and IL-8 from the equivalents, compared to the control without *P. acnes* (Veh-PA, Fig. [5](#Fig5){ref-type="fig"}a, b). Topical SCIO-469 at 4--100 μM inhibited *P. acnes*-induced phospho-p38 dose-dependently (Fig. [5](#Fig5){ref-type="fig"}a) as compared to *P. acnes*-induced plus vehicle-treated control (Veh + PA). In addition, topical SCIO-469 suppressed *P. acnes*-induced secretion of both TNF-α and IL-8 significantly (*p* \< 0.005) at 20 and 100 μM (Fig. [5](#Fig5){ref-type="fig"}b, c). As expected, viable *P. acnes* also induced secretion of IL-1α in the skin equivalents. Inhibition of IL-1α by topical SCIO-469 was also observed, but with no obvious dose-response curve (data not shown).Fig. 5*Propionibacterium acnes*-induced phospho-p38 and cytokine release was inhibited by a p38α inhibitor, SCIO-469, in human epidermal equivalents. **a** Western blot shows that SCIO-469 suppresses *P. acnes*-induced phospho-p38 (p-p38) dose-dependently. **b**--**c** SCIO-469 inhibits the secretion of TNF-α (**b**) and IL-8 (**c**). Data are expressed as mean ± SD. *p* \< 0.05 (\*), *p* \< 0.01 (\*\*), *p* \< 0.005 (\*\*\*). *PA Propionibacterium acnes, TNF* tumor necrosis factor, *IL* interleukin

Discussion {#Sec18}
==========

In this study, p38 MAPK was highly activated in the inflammatory acne lesions compared to normal skin. Using small molecule p38 inhibitors, it was further demonstrated that these compounds not only suppressed *P. acnes*-induced phosphorylation of p38 in vitro, but also decreased *P. acnes*-induced proinflammatory cytokine and chemokine production in keratinocytes in vitro. These data suggest that activation of p38 by *P. acnes* may be one of the contributors to the clinical development of inflammatory acne.

The current study was a pilot investigation on the histological and histochemical skin changes showing there was activation of p38 signaling in inflammatory acne lesions. A limitation of the current study was the small number of acne biopsies that could be obtained and evaluated. Obtaining biopsies of acne lesions was challenging which limits the extrapolation of the results. In addition, this study evaluated p38 only in inflammatory acne lesions; it could be interesting to examine p38 activation in early lesional samples such as comedones.

Exposure of keratinocytes to *P. acnes* induced the activation of multiple MAPK pathways. SB203580, a p38α/β inhibitor, inhibited *P. acnes*-induced phospho-p38. A second p38 pharmacological inhibitor, SCIO-469, specifically inhibited *P. acnes*-induced phospho-p38 in a dose-dependent fashion, suggesting the major isoform activated by *P. acnes* in keratinocytes is p38α. However, when phospho-p38 was blocked by SCIO-469, a concomitant upregulation of phospho-ERK1/2 and phospho-JNK1/2 was observed. This observation was consistent with previous findings \[[@CR40], [@CR44]\]. Similar data were also reported in a wound-healing model and a conditional p38α knock-out mouse model \[[@CR45], [@CR46]\].

*Propionibacterium acnes* stimulates the secretion of proinflammatory cytokines and chemokines such as IL-1, TNF-α, and IL-8 in cultured keratinocytes. IL-1α induces hypercornification of the infundibulum ex vivo, and was detected in the majority of open comedones of acne patients \[[@CR47]--[@CR49]\]. TNF-α may drive the early stage of inflammatory acne lesions \[[@CR5]\]. IL-8 is a potent chemotactic agent for neutrophils, and both IL-8 and neutrophils are commonly found in high levels in inflammatory acne lesions \[[@CR17], [@CR50]\]. IL-8-induced chemotaxis of neutrophils may be activated by endogenous or exogenous (e.g., bacterial) factors to release lysosomal enzymes that can degrade the follicular epithelium, leading to further inflammation \[[@CR51]\]. In lipopolysaccharide (LPS)-stimulated human monocytes, p38α MAPK was the molecular target for the biosynthesis of TNF-α and IL-1 \[[@CR20], [@CR21]\]. Data presented here not only confirm the increased production of TNF-α, IL-8, and IL-1 by keratinocytes upon stimulation with *P. acnes*, but also demonstrated the involvement of p38α MAPK in this process.

Moreover, the biopsies from clinically diagnosed inflammatory acne lesions showed a marked increase of phospho-p38 nuclear staining in follicular and perifollicular epidermal keratinocytes, suggesting translocation of activated p38 to the nuclei. The finding is similar to the localization of activated NK-κB and activator protein-1 (AP-1) in inflammatory acne lesions \[[@CR17]\]. The proliferative effect could be due to the ability of *P. acnes* to activate p38 by stabilizing IL-8 mRNA, and subsequently to upregulate IL-8 secretion resulting in keratinocyte proliferation \[[@CR52]--[@CR55]\]. Both live and heat-killed *P. acnes* can induce phosphorylation of heat shock protein 27, a downstream cellular stress mediator of p38 \[[@CR26]\]. Although our study only focused on acne lesional skin and non-lesional healthy skin, previous studies have reported that non-lesional acne skin adjacent to acne lesions (perilesional) showed overexpression of proinflammatory cytokines (IL-1α) and increased immune cells, but did not exhibit hyperproliferation or abnormal differentiation of the follicular epithelium \[[@CR56]\]. It is interesting to speculate that the presence of inflammation alone is not sufficient to produce acne but perhaps, *P. acnes*-induced inflammatory signaling is an initiating event in comedone formation; however, to produce clinical acne lesions may require a number of *P. acnes*-induced signaling pathways in keratinocytes that affect inflammatory responses, cell proliferation, and hyperkeratinization.

Conclusion {#Sec19}
==========

This study shows an increase in phospho-p38 in biopsies of acne lesions predominantly in follicular and perifollicular keratinocytes. *P. acnes* induces inflammatory responses in cultured keratinocytes and skin epidermal equivalents. p38 MAP kinase inhibitors reduce *P. acnes*-induced inflammation in vitro. These findings, together with the existing evidence showing activation of TLRs and NFκB in acne lesions, indicate that multiple inflammatory signaling molecules are activated in keratinocytes upon stimulation with *P. acnes* and that cross-communication among these mediators may be crucial in the pathogenesis of acne.
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